<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00955890</url>
  </required_header>
  <id_info>
    <org_study_id>MBC0901 FUCH</org_study_id>
    <nct_id>NCT00955890</nct_id>
  </id_info>
  <brief_title>Dexrazoxane as a Protective Agent in Anthracycline Treated Breast Cancer</brief_title>
  <acronym>cardioprotec</acronym>
  <official_title>Randomized Phase II Trial Of Interventional Therapy Investigate Cardiac Protection of Dexrazoxane In Women With Breast Cancer Having Experienced Grade 1 Cardiotoxicity During Prior Anthracycline-based Chemotherapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop
      growing or die. Chemoprotective drugs, such as dexrazoxane, may protect normal cells from the
      side effects of chemotherapy. Monoclonal antibodies such as trastuzumab can locate tumor
      cells and either kill them or deliver tumor-killing substances to them without harming normal
      cells. Radiation therapy uses high-energy x-rays to damage tumor cells. CTnT/cTnI/ANP/BNP
      were proved to be used as a biomarker of drug related cardiotoxicity. There are excellent
      correlations between the total cumulative dose of doxorubicin, the severity of the resulting
      cardiomyopathy, and the level of serum troponin-T.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with breast cancer receiving anthracycline chemotherapy randomized to 3
      groups:chemotherapy plus low dose dexrazoxane,chemotherapy plus middle dose dexrazoxane,
      chemotherapy only.Every patient receive at least 2 cycles anthracycline chemotherapy.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Enrolled too slow
  </why_stopped>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurence of cardiac toxicity in patients with breast cancer receiving anthracycline chemotherapy</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relationship between serum level of cTnT/cTnI/ANP/BNP and cardiac toxicity</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>control arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>anthracycline chemotherapy only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>low dose dexrazoxane group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>anthracycline chemotherapy plus low dose dexrazoxane(10:1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>middle dose dexrazoxane group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>anthracycline chemotherapy plus middle dose dexrazoxane(15:1)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexrazoxane hydrochloride</intervention_name>
    <description>pink power 250mg/bottle DEX:EPI,10:1 every 3 weeks</description>
    <arm_group_label>low dose dexrazoxane group</arm_group_label>
    <arm_group_label>middle dose dexrazoxane group</arm_group_label>
    <other_name>Dexrazoxane for Injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexrazoxane hydrochloride</intervention_name>
    <description>pink powder 250mg/bottle DEX:EPI,15:1 every 3 weeks</description>
    <arm_group_label>middle dose dexrazoxane group</arm_group_label>
    <other_name>dexrazoxane injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed primary infiltrating adenocarcinoma of the breast

               -  Confirmed by core needle biopsy or incisional biopsy or surgery

               -  Experienced grade 1 cardiac toxicity during prior anthracycline-based
                  chemotherapy

               -  At least 2 cycles same anthracycline based chemotherapy are needed

        Exclusion Criteria:

          -  Accumulated dose of EPI ≥1000mg/m2,ADM≥550mg/m2

          -  With the following risk factors: Uncontrolled or severe cardiovascular disease (e.g.,
             myocardial infarction within the past 6 months, congestive heart failure treated with
             medications, or uncontrolled hypertension); Prior or Concurrent radiation to heart

          -  Pregnant or nursing

          -  Other currently active malignancy except nonmelanoma skin cancer

          -  Uncontrolled or severe bleeding,diarrhea,intestinal obstruction

          -  Grade 2 or more Cardiac Toxicity (CTC AE3.0)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>xichun Hu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>member of Fudan University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fudan University Cancer Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 7, 2009</study_first_submitted>
  <study_first_submitted_qc>August 7, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2009</study_first_posted>
  <last_update_submitted>February 27, 2012</last_update_submitted>
  <last_update_submitted_qc>February 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 28, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Xichun Hu</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <keyword>cardioprotection</keyword>
  <keyword>anthracycline chemotherapy</keyword>
  <keyword>breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexrazoxane</mesh_term>
    <mesh_term>Razoxane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

